Table 2. Demographic, clinical data and outcome by diagnosis group.
| Viral N=80 | Indeterminate N=436 | Other N=344 | p-valuea | p-valueb | p-valuec | p-valued | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Age at enrollment (years) | <0.0001& | <0.0001# | <0.0001# | NS# | |||
| N | 80 | 436 | 344 | ||||
| Median | 0.6 | 3.7 | 4.3 | ||||
| Range | 0.0-17.9 | 0.0-17.9 | 0.0-17.9 | ||||
| 0 – 6 months old | 39 (48.8%) | 81 (18.6%) | 100 (29.1%) | <0.0001$ | <0.0001$ | 0.0007$ | 0.0006$ |
| ➢ 6 months old | 41 (51.3%) | 355 (81.4%) | 244 (70.9%) | ||||
|
| |||||||
| Total bilirubin at enrollment (mg/dL) | <0.0001& | 0.0005# | NS# | <0.0001# | |||
| N | 65 | 385 | 288 | ||||
| Median | 9.1 | 14.2 | 8.8 | ||||
| Range | 0.3-39.0 | 0.2-43.1 | 0.4-63.4 | ||||
|
| |||||||
| INR at enrollment | 0.0003& | NS# | 0.016# | 0.0001# | |||
| N | 70 | 381 | 296 | ||||
| Median | 2.8 | 2.7 | 2.5 | ||||
| Range | 1.3-13.7 | 1.0-63.9 | 1.0-13.0 | ||||
|
| |||||||
| ALT at enrollment (IU/L) | <0.0001& | NS# | 0.0003# | <0.0001# | |||
| N | 67 | 375 | 289 | ||||
| Median | 909 | 1732 | 582 | ||||
| Range | 103-8681 | 18-18524 | 7-13372 | ||||
|
| |||||||
| 21-day outcome | <0.0001$ | <0.0001$ | NS$ | <0.0001$ | |||
| Death without LT | 22 (27.5%) | 42 (9.6%) | 53 (15.4%) | ||||
| LT | 13 (16.3%) | 194 (44.5%) | 77 (22.4%) | ||||
| Survival without LT | 45 (56.3%) | 200 (45.9%) | 214 (62.2%) | ||||
NS=not significant after Bonferroni correction (p-value >0.0167)
a
p-value across the three diagnosis groups.
b
p-value for the comparison between “Viral” and “Indeterminate”
c
p-value for the comparison between “Viral” and “Other”
d
p-value for the comparison between “Indeterminate” and “Other”
$
From Pearson's chi-square test of association
&
From Kruskal-Wallis test
#
From Mann-Whitney test